SUZHOU, China, Oct. 8, 2021 /PRNewswire/ — CStone Pharmaceuticals (“CStone”, HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the data on the preclinical characterization of the potentially global best-in-class drug CS5001(ROR1 ADC) was accepted in a late-breaking abstract (LBA) session as a virtual poster presentation at the 33rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021(Poster ID:LBA008). The results showed that CS5001 exhibited potent and selective cytotoxicity to a variety of ROR1-expressing cell lines and demonstrated remarkable in vivo antitumor activity in xenograft mouse models. ROR1 expression appears to predict sensitivity to CS5001 in a panel of cancer cell lines. Our data indicated that CS5001 is a promising therapeutic candidate for the treatment of ROR1-expressing hematological and solid malignancies with precision medicine potential.
The work was collaboratively accomplished by CStone, LegoChem Biosciences (“LCB”), Inc., Daejeon, Republic of Korea and ABL Bio, Seongnam, Republic of Korea.
- Presentation session: Multiple solid and hematological malignancies
- Date: October 7-10, 2021
- Format: Late-breaking abstract (LBA)
- Title: CS5001, a novel ROR1-targeting antibody drug conjugate (ADC) armed with tumor-cleavable β-glucuronide linkers and pyrrolobenzodiazepine (PBD) prodrugs for hematological and solid malignancies
- Speakers/Leading Principal Investigator: Dr. Archie N. Tse, Chief Scientific Officer of CStone
CS5001 is an ADC composed of a human monoclonal antibody targeting ROR1, site-specifically conjugated with a proprietary cleavable β-glucuronide linker to a prodrug of PBD dimer. Both linker and prodrug are selectively cleaved by the lysosomal β-glucuronidase, which is overexpressed in many cancerous cells, to allow tumor-selective release of the DNA-crosslinking PBD dimer.
CS5001 bound specifically to human ROR1, but not ROR2. CS5001 has cross reactivity against mouse, rat and cynomolgus ROR1 at similar affinities. Upon binding, CS5001 was rapidly internalized by ROR1-expressing cancer cells. CS5001 demonstrated potent cytotoxicity towards ROR1 high expressing cell lines such as Jeko-1 (mantle cell lymphoma) and MDA-MB-231 (triple-negative breast cancer), with sub-nanomolar IC50 values. The growth inhibition activity of CS5001 was significantly correlated with ROR1 density in a panel of cancer cell lines.
CS5001 exhibited prominent antitumor activity in both Jeko-1 and MDA-MB-231 xenograft models in a dose-dependent manner. In addition, CS5001 demonstrated superior efficacy compared to an MMAE-based ROR1 ADC at equitoxic doses in the Jeko-1 model.
Dr. Archie Tse, Chief Scientific Officer of CStone, said: “ROR1 is a very promising target as it is differentially expressed in a variety of solid and hematological malignancies but not in normal adult tissues. This means that ROR1 has the potential to be an oncological target like PD-(L)1 for a broad spectrum of cancers. The preclinical pharmacology and biomarker data presented at the conference were encouraging and demonstrated the precision medicine potential of CS5001 for the treatment of multiple hematological and solid malignancies. We expect Investigational New Drug (“IND”) filing by year end and clinical testing shortly thereafter.”
CS5001 is a pre-clinical ADC completing IND enabling studies. CS5001 has a uniquely design tumor-cleavable linker that is conjugated to a LCB’s proprietary pyrrolobenzodiazepine (PBD) prodrug. Only after reaching the tumor, the linker and prodrug are cleaved to release the PBD toxin, resulting in lethal DNA cross-links in cancer cells. The use of the linker plus PBD prodrug effectively helps addressing the toxicity problem associated with traditional PBD payloads, leading to a better safety profile. Additionally, CS5001 utilizes site-specific conjugation for a precise drug antibody ratio of 2 which enables homogeneous production and large-scale manufacturing.
In October 2020, CStone signed a licensing agreement with LCB for the development and commercialization of CS5001. Under the agreement, CStone obtains the exclusive global right to lead development and commercialization of CS5001 outside the Republic of Korea.
CStone Pharmaceuticals (HKEX: 2616) is a biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, CStone has received three drug approvals in Greater China, including two in Mainland China and one in Taiwan. CStone’s vision is to become globally recognized as a world-renowned biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.
For more information about CStone, please visit: www.cstonepharma.com.
The forward-looking statements made in this article only relate to events or information as of the date when the statements are made in this article. Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. All statements in this article are made on the date of publication of this article and may change due to future developments.